MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

Merck on Thursday said it has secured an exclusive global license to develop, manufacture and commercialize LM-299, an investigational PD-1/VEGF bispecific antibody from Shanghai-based LaNova that is ...